Answers are grounded in this paper and cite their sources.
Recessive dystrophic epidermolysis bullosa (RDEB) is defined by severe chronic skin fragility due to mutations in COL7A1, the gene encoding type VII collagen. From birth, pressure or friction shears the epidermis producing large blisters, giving the newborns the name ‘Butterfly babies’. Great advances in cell and protein therapies have resulted in improvements for the patients. However, there are drawbacks associated with current clinical strategies which require intensive pretreatment to already delicate bodies. Integrative viral gene therapy is problematic, as systemic delivery retains a statistical level of harmful mutagenesis due to the highly proliferative nature of keratinocytes and the already frequent incidence of cancers in patients with RDEB 1. Ex vivo gene therapy clinical trials have previously been developed for RDEB but performing significant surgeries to an already fragile, scarred epidermis is a significant downside. For clinical application of any gene therapy, the multiple accessory sequences that allow for plasmid DNA manufacture as well as the antibiotic resistance sequences have negative effects once in eukaryotic cells and thus must be removed 2. To achieve this, production of a therapeutic gene in a minicircle (MC) construct is advantageous. Multiple approaches to produce these MC constructs have shown a 10- to 100-fold higher and more stable non-integrative transgene expression in vivo 3. Our previously published studies have indicated that a highly branched poly (β-amino ester) HPAE can mediate a 22.3- and 3.4-fold increase in transfection efficiency in keratinocytes when compared to the commercial transfection agents PEI and SuperFect, respectively, also with much lower cytotoxicity than these commercial gold standards 4. We postulated that a polymeric gene vector with a minimized non-integrating DNA construct could be applied to the skin by injection or topically and restore the expression of type VII collagen to human RDEB skin. For efficient delivery to RDEB skin cells, MC DNA expressing the full COL7A1 cDNA (MCC7) has been produced to form polyplexes with a recently designed HPAE, developed for epidermal cells 4. These polyplexes were tested in vitro and in vivo to determine their ability to return expression of recombinant type VII collagen to keratinocytes. After insertion of COL7A1 into the parental plasmid MN512A1 (Systems Bioscience, CA, USA), intra-molecular recombination successfully removed the accessory sequences of the plasmid (Fig. 1b). The HPAE used in this study had a molecular weight (Mw) of 11,649 Da with a polydispersity index (PDI) of 3.7 (Fig. 1a). The Mark–Houwink plot alpha value (α) of 0.46 indicated its highly branched architecture 4. The optimal HPAE we have tested exhibited strong DNA binding affinity and can effectively bind DNA to formulate polyplexes with an average size around 182 ± 5.7 nm (Fig. S1abc). A dose of polyplexes was applied to the RDEBK-TA4 cell line 5, and this 40 μg of MCC7 complexed with 1.2 mg of HPAE achieved a comparable level or recombinant protein expression to that produced by primary keratinocytes (Fig. S2). This indicated a therapeutically sufficient amount of protein could be produced in vivo as it has been reported for phenotypic correction a minimum 35%–50% of the standard amount of type VII collagen is required 6, 7. Following this and other in vitro assessments, a murine grafting model was generated with human RDEB skin 8. Three animals that had been grafted with human RDEB skin received a single intra-dermal injection of the HPAE-MCC7 polyplexes, only one of which was then positive for the recombinant protein by day 5. However, once multiple doses of the polyplexes were delivered to the animals (2× or 3×), all of the skin grafts were then found to be positive for the recombinant protein (Fig. 2). Most importantly, we further assessed the effectiveness of the HPAE-MCC7 utilizing the most favourable administration route – topical application. A topically applied therapy could distribute the type VII collagen protein production much further than the current ex vivo correction systems. Five days after a single topical application, recombinant protein could be visualized at points along the basement membrane zone (BMZ) (Fig. S4a). Type VII collagen expression was visible at 10 weeks after three topical applications throughout the length of the human RDEB graft BMZ (Fig. 2b). For in vivo applications, a total of 20 μg of MCC7 was complexed with 600 μg HPAE, diluted in NaAc (5 mm, pH = 5.2) and injected intra-dermally. With topical applications, the polyplex solution was directly dropped on the grafts after the area was tapped 10 times with a mild adhesive tape. Untreated RDEB grafts also produced from primary type VII collagen null keratinocytes, and fibroblasts were used as a negative control (Fig. S4bc). As expected, no fluorescent signal was detected along the BMZ of these samples. As a positive control, we grafted skin equivalents generated with wild-type human primary keratinocytes expressing type VII collagen. Haematoxylin and eosin staining of all the treated tissue samples showed a morphologically normal epidermis with adhesion to the dermis without blistering (Fig. S5). Episomal transgenes are highly attractive for topical clinical use in the rapidly proliferating keratinocyte population as they avoid potential mutagenicity. It is theorized that MC DNA may even effect a larger area in vivo than the standard plasmid gene therapy 9. The increased diffusion coefficient through tissue of small particles such as HPAE-MC7 is very attractive for dermatological conditions like RDEB. Complexing MCC7 with a polymeric vector is ideal for genodermatoses due to ease of formulation for the treatment of large areas. The low-cost components are stable and individually innocuous, the polyplexes are simple to form and prepare for in vivo use, and they can be formulated at a concentrated dose in a small (40–60 μl) volume. The results seen after a simple repeated dosing regimen are a positive indication for the future of non-viral gene therapy for the treatment of genetic skin conditions. Funded by the Science Foundation Ireland, the Health Research Board, University College Dublin and DEBRA Ireland. LC and DZ performed majority of work, and LC wrote the paper. XH, FL and BD provided technical assistance. UG assisted in paper writing. WW oversaw study. The authors have declared no conflicting interests. Figure S1. Characterization of HPAE/DNA polyplexes. Figure S2. Immunoblot data. Figure S3. Treatment regime. Figure S4. Immunofluorescence images of skin grafts. Figure S5. Immuno-histological staining. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Cutlar et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: